Published in The Delta Rx Institute/Drake University, Written in collaboration with F. Randy Vogenberg, PhD, RPh Partner, Access Market Intelligence and The National Institute of Collaborative Healthcare Pharmacists are some of the most visible health professionals to the public eye, but they often stand misunderstood by purchasers of health care. They are best known for […]
Employers as Plan Sponsors: Direct to Purchaser, Published at Drake University Delta Rx Institute, Dr. F. Randy Vogenberg, Partner Access Market Intelligence, an affiliate of the National Institute of Collaborative Healthcare Pharmacists are some of the most visible health professionals to the public eye, but they often stand misunderstood by purchasers of health care. They are best known […]
Employers Medical Stop Loss for Specialty Rxs – Employers will continue to experience escalating specialty Rx costs. Effective but expensive non-substitutable products emerging from pharmaceutical manufacturers’ development pipelines will quickly and sharply drive both pharmacy and medical benefit year-over-year spending increases. Traditional risk management tools, like stop loss insurance policies are designed to mitigate risk […]
Benefit Design – A Call to Action to Address Burden of Unintended Pregnancies in Plans’ Benefit Design F. Randy Vogenberg, PhD, RPh Partner, Access Market Intelligence, Greenville, SC Adjunct Professor of Pharmacy Administration, Presbyterian College School of Pharmacy, Clinton, SC Adjunct Instructor, Outcomes and Health Policy, University of Illinois at Chicago College of Pharmacy Originally […]
Gilead Sciences’ ($GILD) hep C drug Sovaldi burst onto the market, impressing doctors and patients with its benefits and outraging payers and politicians with its price. It reached blockbuster status twice over in the course of a single quarter. But instead of an aberration, a new report suggests it is a reflection of a trend that has […]